Subscribe to RSS
DOI: 10.1055/s-0029-1242011
© Georg Thieme Verlag KG Stuttgart · New York
„TRECID”: TNFα-assoziierte chronisch entzündliche Erkrankungen
Eine neue Krankheits-übergreifende Sichtweise„TRECID”, TNFα related chronic inflammatory diseasesA new multiple diseases bridging conceptPublication History
eingereicht: 13.3.2009
akzeptiert: 23.7.2009
Publication Date:
06 October 2009 (online)

Zusammenfassung
In der Pathogenese infektiöser und entzündlicher Erkrankungen nimmt das proinflammatorische Zytokin TNFα eine Schlüsselposition ein. Die Aufklärung seiner zentralen Rolle in der Pathogenese von rheumatoider Arthritis, Spondyloarthritiden, Uveitis, Psoriasis und bei chronisch entzündlichen Darmerkrankungen hat zur Entwicklung von gegen TNFα gerichteten Therapien geführt, bei denen eine Erkrankungs-modifizierende Wirksamkeit beobachtet wird, die über diejenige früherer Therapieoptionen hinausgehen kann.
Befunde über das Auftreten weiterer chronisch entzündlicher Autoimmunerkrankungen bei Patienten, die bereits an einer solchen Erkrankung leiden, haben zur Hypothese geführt, dass gemeinsame pathologische Prozesse dieser Zytokin-Dysregulation zugrunde liegen könnten. Entsprechend wurde der Begriff TRECID als Oberbegriff für TNFα-assoziierte chronisch entzündliche Erkrankungen entwickelt.
Ärzte verschiedener Fachdisziplinen haben aufgrund dieser Pathophysiologie in den letzten Jahren neue Therapieoptionen mit TNFα-Blockern in ihr Behandlungskonzept integriert. Das TRECID-Konzept kann daher als Modell für eine dynamische, Disziplin-übergreifende Zusammenarbeit auf gemeinsamer pathophysiologischer Basis gelten.
Summary
The pro-inflammatory cytokine TNF alpha (TNF) has a key position in the pathogenesis of various infectious and inflammatory diseases. Clarification of its pivotal role in the pathogenesis of rheumatoid arthritis, spondyloarthritis, uveitis, psoriasis and inflammatory bowel disease has resulted in the successful development of TNF- blocking therapies, which have disease-modifying properties that exceed the effects of conventional therapeutic options. For this reason data on the concurrence of several chronic inflammatory diseases have led to the hypothesis of common pathogenetic processes of cytokine dysregulation. The acronym TRECID describes this concept of „TNF RElated Chronic Inflammatory Diseases”. Physicians of different specialties have integrated new therapeutic options with TNF-blocking therapies into their strategies for the management of the affected patients. Thus the concept of TRECID can be regarded as a role model for a dynamic, interdisciplinary cooperation based on shared pathophysiological aspects.
Schlüsselwörter
TRECID - TNFα - rheumatoide Arthritis - Spondyloarthritis - chronisch entzündliche Darmerkrankungen - Psoriasis - Psoriasisarthritis - Uveitis
Keywords
TRECID - TNFα - rheumatoid arthritis - ankyloarthritis - inflammatory bowel disease - psoriasis - psoriasis arthritis - uveitis
Literatur
- 1
Barrett J C, Hansoul S, Nicolae D L. et al .
Genome-wide association
defines more than 30 distinct susceptibility loci for Crohn’s
disease.
Nat Genet.
2008;
40
955-962
MissingFormLabel
- 2
Bjarnason I, Helgason K O, Geirsson A J. et al .
Subclinical intestinal inflammation
and sacroiliac changes in relatives of patients with ankylosing
spondylitis.
Gastroenterology.
2003;
125
1598-1605
MissingFormLabel
- 3
Boehncke W H, Friedrich M, Kaltwasser J P. et al .
Psoriasis-Arthritis – eine interdisziplinäre
Herausforderung.
Dtsch Arztebl.
2006;
103
1455-1461
MissingFormLabel
- 4
Boyman O, Hefti H P, Conrad C, Nickoloff B J, Suter M, Nestle F O.
Spontaneous
development of psoriasis in a new animal model shows an essential
role for resident T cells and tumor necrosis factor-alpha.
J Exp
Med.
2004;
199
731-736
MissingFormLabel
- 5
Braun J, Bollow M, Neure L. et
al .
Use of immunohistologic and in situ hybridization
techniques in the examination of sacroiliac joint biopsy specimens
from patients with ankylosing spondylitis.
Arthritis Rheum.
1995;
38
499-505
MissingFormLabel
- 6
Breedveld F C, Weisman M H, Kavanaugh A F. et al .
The PREMIER study: A multicenter,
randomized, double-blind clinical trial of combination therapy with
adalimumab plus methotrexate versus methotrexate alone or adalimumab
alone in patients with early, aggressive rheumatoid arthritis who
had not had previous methotrexate treatment.
Arthritis
Rheum.
2006;
54
26-37
MissingFormLabel
- 7
Brito B E, O’Rourke L M, Pan Y, Anglin J, Planck S R, Rosenbaum J T.
IL-1 and TNF receptor-deficient mice show decreased inflammation
in an immune complex model of uveitis.
Invest Ophthalmol
Vis Sci.
1999;
40
2583-2589
MissingFormLabel
- 8
Brophy S, Pavy S, Lewis P. et
al .
Inflammatory eye, skin, and bowel disease in spondyloarthritis:
genetic, phenotypic, and environmental factors.
J Rheumatol.
2001;
28
2667-2673
MissingFormLabel
- 9
Brophy S, Taylor G, Blake D, Calin A.
The interrelationship between sex, susceptibility
factors, and outcome in ankylosing spondylitis and its associated
disorders including inflammatory bowel disease, psoriasis, and iritis.
J Rheumatol.
2003;
30
2054-2058
MissingFormLabel
- 10 Colombel J F, Rutgeerts P, Reinisch W. et al .SONIC: A randomized, double-blind,
controled trial comparing infliximab and infliximab plus azathioprine
to azathioprine in patients with Crohn’s disease naive
to immunomodulators and biologic therapy. 16th United European Gastroenterology
Week. Abstract OP001. Wien, Österreich; 20.10.2008
MissingFormLabel
- 11
D’Haens G, Baert F, van Assche G. et al .
Early combined immunosuppression or conventional
management in patients with newly diagnosed Crohn’s disease:
an open randomised trial.
Lancet.
2008;
371
660-667
MissingFormLabel
- 12
Danese S, Semeraro S, Papa A. et al .
Extraintestinal manifestations in inflammatory
bowel disease.
World J Gastroenterol.
2005;
11
7227-7236
MissingFormLabel
- 13
Gottlieb A B, Evans R, Li S. et
al .
Infliximab induction therapy for patients with
severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled
trial.
J Am Acad Dermatol.
2004;
51
534-542
MissingFormLabel
- 14
Hampe J, Franke A, Rosenstiel P. et al .
A genome-wide association scan of nonsynonymous
SNPs identifies a susceptibility variant for Crohn disease in ATG16L1.
Nat Genet.
2007;
39
207-211
MissingFormLabel
- 15
Hanauer S B.
Inflammatory bowel disease: epidemiology, pathogenesis, and
therapeutic opportunities.
Inflamm Bowel Dis.
2006;
12 Suppl 1
S3-9
MissingFormLabel
- 16
Hyams J, Crandall W, Kugathasan S. et al .
Induction and maintenance infliximab therapy
for the treatment of moderate-to-severe Crohn’s disease in
children.
Gastroenterology.
2007;
132
863-873; quiz 1165–1166
MissingFormLabel
- 17
Krüger K, Augustin M, Rauch C, Reich K.
Prevalence and clinical
manifestation of arthritis in a daily practice psoriasis population – a
prospective observational epidemiological study in Germany.
Ann
Rheum Dis.
2006;
65
531;
Abs SAT0265
MissingFormLabel
- 18
Lee F I, Bellary S V, Francis C.
Increased occurrence of psoriasis in patients with Crohn’s
disease and their relatives.
Am J Gastroenterol.
1990;
85
962-963
MissingFormLabel
- 19
Loftus Jr E V.
Biologic therapy in Crohn’s disease:
review of the evidence.
Rev Gastroenterol Disord.
2007;
7 Suppl 1
S3-S12
MissingFormLabel
- 20
Luyten F P, Lories R J, Verschueren P, de Vlam K, Westhovens R.
Contemporary concepts of inflammation, damage
and repair in rheumatic diseases.
Best Pract Res Clin
Rheumatol.
2006;
20
829-848
MissingFormLabel
- 21
Märker-Hermann E, Frauendorf E, Zeidler H, Sieper J.
Pathogenese
der ankylosierenden Spondylitis – Mechanismen der Krankheitsentstehung
und Chronifizierung [Pathogenesis of ankylosing spondylitis-mechanisms
of disease manifestation and chronicity].
Z Rheumatol.
2004;
63
187-192
MissingFormLabel
- 22
Matsuo T, Koyama T, Morimoto N, Umezu H, Matsuo N.
Retinal vasculitis as a complication of rheumatoid arthritis.
Ophthalmologica.
1990;
201
196-200
MissingFormLabel
- 23
Mielants H, Veys E M, Cuvelier C, De Vos M.
Course of gut inflammation in
spondylarthropathies and therapeutic consequences.
Baillieres Clin
Rheumatol.
1996;
10
147-164
MissingFormLabel
- 24
Mrowietz U, Elder J T, Barker J.
The importance of disease associations and concomitant therapy
for the long-term management of psoriasis patients.
Arch
Dermatol Res.
2006;
298
309-319
MissingFormLabel
- 25
Murphy C C, Ayliffe W H, Booth A, Makanjuola D, Andrews P A, Jayne D.
Tumor necrosis
factor alpha blockade with infliximab for refractory uveitis and
scleritis.
Ophthalmology.
2004;
111
352-356
MissingFormLabel
- 26
Nissinen R, Leirisalo-Repo M, Nieminen A M. et al .
Immune activation in the
small intestine in patients with rheumatoid arthritis.
Ann Rheum
Dis.
2004;
63
1327-1330
MissingFormLabel
- 27
Papp K A, Tyring S, Lahfa M. et al .
A global phase III randomized controlled
trial of etanercept in psoriasis: safety, efficacy, and effect of dose
reduction.
Br J Dermatol.
2005;
152
1304-1312
MissingFormLabel
- 28
Persson P G, Leijonmarck C E, Bernell O, Hellers G, Ahlbom A.
Risk indicators for inflammatory bowel disease.
Int J Epidemiol.
1993;
22
268-272
MissingFormLabel
- 29
Quinn M A, Conaghan P G, O’Connor P J. et al .
Very early treatment
with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid
arthritis reduces magnetic resonance imaging evidence of synovitis
and damage, with sustained benefit after infliximab withdrawal:
results from a twelve-month randomized, double-blind, placebo-controlled
trial.
Arthritis Rheum.
2005;
52
27-35
MissingFormLabel
- 30
Rabinovich C E.
Use of tumor necrosis factor inhibitors in uveitis.
Curr Opin
Rheumatol.
2007;
19
482-486
MissingFormLabel
- 31
Reich K, Hüffmeier U, König I R. et al .
TNF polymorphisms
in psoriasis: Association of psoriatic arthritis with the promoter
polymorphism TNF*-857 independent of the PSORS1 risk allele.
Arthritis Rheum.
2007;
56
2056-2064
MissingFormLabel
- 32
Reich K, Nestle F O, Papp K. et al .
Infliximab induction and maintenance therapy
for moderate-to-severe psoriasis: a phase III, multicentre, double-blind
trial.
Lancet.
2005;
366
1367-1374
MissingFormLabel
- 33
Reveille J D, Arnett F C.
Spondyloarthritis:
update on pathogenesis and management.
Am J Med.
2005;
118
592-603
MissingFormLabel
- 34
Rogler G, Brand K, Vogl D. et
al .
Nuclear factor kappaB is activated in macrophages
and epithelial cells of inflamed intestinal mucosa.
Gastroenterology.
1998;
115
357-369
MissingFormLabel
- 35
Rudwaleit M, Baeten D.
Ankylosing spondylitis
and bowel disease.
Best Pract Res Clin Rheumatol.
2006;
20
451-471
MissingFormLabel
- 36
Rutgeerts P.
Modern therapy for inflammatory bowel disease.
Scand
J Gastroenterol Suppl.
2003;
237
30-33
MissingFormLabel
- 37
Rutgeerts P, Sandborn W J, Feagan B G. et al .
Infliximab for induction and
maintenance therapy for ulcerative colitis.
N Engl J Med.
2005;
353
2462-2476
MissingFormLabel
- 38
Santos Lacomba M, Marcos Martin C, Gallardo Galera J M. et al .
Aqueous Humor
and Serum Tumor Necrosis Factor-alpha in Clinical Uveitis.
Ophthalmic
Research.
2001;
33
251-255
MissingFormLabel
- 39
Sartor R B.
Importance of intestinal mucosal immunity and luminal bacterial
cell wall polymers in the aetiology of inflammatory joint diseases.
Baillieres Clin Rheumatol.
1989;
3
223-245
MissingFormLabel
- 40
Saurenmann R K, Levin A V, Rose J B. et al .
Tumour necrosis factor alpha inhibitors
in the treatment of childhood uveitis.
Rheumatology (Oxford).
2006;
45
982-989
MissingFormLabel
- 41
Schreiber S, Nikolaus S, Hampe J.
Activation of nuclear factor kappa B inflammatory bowel disease.
Gut.
1998;
42
477-484
MissingFormLabel
- 42
Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M.
Genetics of Crohn disease, an archetypal inflammatory barrier
disease.
Nat Rev Genet.
2005;
6
376-388
MissingFormLabel
- 43
Scott D L, Kingsley G H.
Tumor necrosis
factor inhibitors for rheumatoid arthritis.
N Engl J Med.
2006;
355
704-712
MissingFormLabel
- 44
Simmonds R E, Foxwell B M.
Signalling,
inflammation and arthritis: NF-kappaB and its relevance to arthritis
and inflammation.
Rheumatology (Oxford).
2008;
47
584-590
MissingFormLabel
- 45
Suhler E B, Smith J R, Wertheim M S. et al .
A prospective trial of infliximab
therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Arch Ophthalmol.
2005;
123
903-912
MissingFormLabel
- 46
Taylor P C, Williams R O, Feldmann M.
Tumour necrosis factor alpha as a therapeutic target for immune-mediated
inflammatory diseases.
Curr Opin Biotechnol.
2004;
15
557-563
MissingFormLabel
- 47
van der Heijde D, Klareskog L, Rodriguez-Valverde V. et al .
Comparison of etanercept
and methotrexate, alone and combined, in the treatment of rheumatoid
arthritis: two-year clinical and radiographic results from the TEMPO
study, a double-blind, randomized trial.
Arthritis Rheum.
2006;
54
1063-1074
MissingFormLabel
- 48
van Roon J A, Bijlsma J W, Lafeber F P.
Diversity of regulatory T cells to control
arthritis.
Best Pract Res Clin Rheumatol.
2006;
20
897-913
MissingFormLabel
- 49
Villani A C, Lemire M, Fortin G. et al .
Common variants in the NLRP3 region contribute
to Crohn’s disease susceptibility.
Nat Genet.
2009;
41
71-76
MissingFormLabel
- 50
Watanabe T, Kitani A, Strober W.
NOD2 regulation of Toll-like receptor responses and the pathogenesis
of Crohn’s disease.
Gut.
2005;
54
1515-1518
MissingFormLabel
- 51
Williams J P, Meyers J A.
Immune-mediated
inflammatory disorders (I.M.I.D.s): the economic and clinical costs.
Am J Manag Care.
2002;
8
S664-681; quiz S682–665
MissingFormLabel
- 52
Zochling J, van der Heijde D, Burgos-Vargas R. et al .
ASAS/EULAR recommendations
for the management of ankylosing spondylitis.
Ann Rheum Dis.
2006;
65
442-452
MissingFormLabel
Prof. Dr. Ulf Müller-Ladner
Lehrstuhl für Innere Medizin mit Schwerpunkt
Rheumatologie, Justus-Liebig Universität Giessen, Abt.
für Rheumatologie und Klinische Immunologie, Kerckhoff-Klinik
Benekestraße 2-8
61231 Bad Nauheim
Phone: 06032/9962101
Email: u.mueller-ladner@kerckhoff-klinik.de